- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Dec 4, 2024
Product Development
Confidence in masked T cell engagers builds with Janux update
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Nov 27, 2024
Product Development
The late-stage pancreatic cancer landscape: innovation level modest
PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting
BioCentury | Oct 9, 2024
Product Development
TYK2 best-in-class battleground expands with InnoCare data
In BioCentury’s latest Clinical Report: Sage misses in early Alzheimer’s, and a Phase III setback for J&J’s bladder cancer delivery device
BioCentury | Sep 27, 2024
Regulation
Again, with feeling: FDA urges PD-L1 standardization, patient stratification
ODAC votes against use of PD-1 mAbs for PD-L1 low gastric, esophageal cancers
BioCentury | Apr 30, 2024
Data Byte
EMA’s CHMP recommends Takeda VEGF therapy, Idorsia hypertension drug
April opinions also include earlier-line use of J&J’s Rybrevant and BMS’s Opdivo
BioCentury | Apr 27, 2024
Data Byte
FDA label expansions: March brought full approvals of Elahere, Rybrevant
Plus: Approvals in earlier cancer lines for Rybrevant and Opdivo, and new indications for four more products
BioCentury | Oct 20, 2023
Product Development
J&J takes on Tagrisso in lung cancer, builds bladder cancer foundation
Johnson & Johnson presents trove of data on bispecific antibody Rybrevant at the ESMO 2023 Congress
BioCentury | Nov 9, 2022
Product Development
Ipsen pancreatic cancer readout sets up reward for Merrimack shareholders’ patience
Effectively non-operational since 2019, the biotech could receive milestones tied to Onivyde and pay them out as a dividend
Items per page:
1 - 10 of 1238